Comparing of Dicerna Pharmaceuticals Inc. (DRNA) and Sage Therapeutics Inc. (NASDAQ:SAGE)

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and Sage Therapeutics Inc. (NASDAQ:SAGE), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals Inc. 6.18M 142.58 88.85M -2.23 0.00
Sage Therapeutics Inc. 90.27M 89.24 372.88M -8.06 0.00

In table 1 we can see Dicerna Pharmaceuticals Inc. and Sage Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and Sage Therapeutics Inc. (NASDAQ:SAGE)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals Inc. -1,437.70% -90.8% -74.4%
Sage Therapeutics Inc. -413.07% -37.4% -35.3%

Risk & Volatility

Dicerna Pharmaceuticals Inc. has a 2.39 beta, while its volatility is 139.00%, thus making it more volatile than Standard & Poor’s 500. Sage Therapeutics Inc.’s 193.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 2.93 beta.


The Current Ratio and a Quick Ratio of Dicerna Pharmaceuticals Inc. are 6.3 and 6.3. Competitively, Sage Therapeutics Inc. has 11 and 11 for Current and Quick Ratio. Sage Therapeutics Inc.’s better ability to pay short and long-term obligations than Dicerna Pharmaceuticals Inc.

Analyst Recommendations

Dicerna Pharmaceuticals Inc. and Sage Therapeutics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dicerna Pharmaceuticals Inc. 0 0 7 3.00
Sage Therapeutics Inc. 1 0 6 2.86

$24.57 is Dicerna Pharmaceuticals Inc.’s average target price while its potential upside is 90.32%. On the other hand, Sage Therapeutics Inc.’s potential upside is 20.29% and its average target price is $190.29. Based on the results delivered earlier, Dicerna Pharmaceuticals Inc. is looking more favorable than Sage Therapeutics Inc., analysts opinion.

Institutional & Insider Ownership

Roughly 99.3% of Dicerna Pharmaceuticals Inc. shares are held by institutional investors while 0% of Sage Therapeutics Inc. are owned by institutional investors. About 9.16% of Dicerna Pharmaceuticals Inc.’s share are held by insiders. On the other hand, insiders held about 1.4% of Sage Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dicerna Pharmaceuticals Inc. 19.55% 23.96% -14% -18.49% 0% 19.55%
Sage Therapeutics Inc. -2.38% 9.11% 41.4% -1.83% -3.58% 62.42%

For the past year Dicerna Pharmaceuticals Inc. was less bullish than Sage Therapeutics Inc.


On 7 of the 12 factors Sage Therapeutics Inc. beats Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.